Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Malaria

Interventions

BIOLOGICAL

R21/Matrix-M™

Adjuvanted malaria vaccine

Trial Locations (1)

MRC/UVRI & LSHTM Uganda Research Unit, Entebbe

All Listed Sponsors

collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

lead

University of Oxford

OTHER